Cargando…

Preparation & in vitro evaluation of (90)Y-DOTA-rituximab

BACKGROUND & OBJECTIVES: Radioimmunotherapy is extensively being used for the treatment of non-Hodgkin's lymphoma (NHL). Use of rituximab, a chimeric anti-CD20 antibody directed against the CD20 antigen in combination with suitable beta emitters is expected to result in good treatment respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kameswaran, Mythili, Pandey, Usha, Dash, Ashutosh, Samuel, Grace, Venkatesh, Meera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822370/ https://www.ncbi.nlm.nih.gov/pubmed/26997015 http://dx.doi.org/10.4103/0971-5916.178593

Ejemplares similares

Preliminary evaluation of indigenous (90)Y-labelled microspheres for therapy of hepatocellular carcinoma
por: Subramanian, Suresh, et al.
Publicado: (2016)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Rhenium-188 Hydroxyethane 1,1-Diphosphonic Acid (HEDP) for Bone Pain Palliation Using BARC-HEDP Kits versus Pars-HEDP Kits: A Comparison on Preparation and Performance Aspects at Hospital Radiopharmacy
por: Ramakurup, Radhakrishnan Edathuruthy Kalarickal, et al.
Publicado: (2018)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm
por: Albertoni, Claudio, et al.
Publicado: (2015)

Evaluation and comparison of human absorbed dose of (90)Y-DOTA-Cetuximab in various age groups based on distribution data in rats
por: Vakili, Ariandokht, et al.
Publicado: (2012)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy
por: Ackova, Darinka Gjorgieva, et al.
Publicado: (2016)

Radioligand Therapy with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Preparation and preclinical evaluation of (68)Ga-DOTA-amlodipine for L-type calcium channel imaging
por: Firuzyar, Tahereh, et al.
Publicado: (2016)

Somatostatin-based radiotherapy with [(90)Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
por: Marincek, Nicolas, et al.
Publicado: (2013)

Labelling of (90)Y- and (177)Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis
por: Iori, Michele, et al.
Publicado: (2017)

Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid
por: Kahnt, Michael, et al.
Publicado: (2019)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

In Vitro Characterization of (177)Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer
por: Mohajershojai, Tabassom, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
por: Casey, J. L., et al.
Publicado: (1998)

Clinical utility of (188)Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies
por: Shinto, Ajit S., et al.
Publicado: (2018)

Preparation, biological characterization and preliminary human imaging studies of (68)Ga-DOTA-IBA
por: Wang, Yingwei, et al.
Publicado: (2022)

Synthesis of a DOTA-C-glyco bifunctional chelating agent and preliminary in vitro and in vivo study of [(68)Ga]Ga-DOTA-C-glyco-RGD
por: Mangin, Floriane, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

(44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
por: Domnanich, Katharina A., et al.
Publicado: (2016)

Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy
por: Wang, Wenbo, et al.
Publicado: (2020)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

Mélanocytose oculopalpébrale ou naevus d'Ota
por: Elouarradi, Hakima, et al.
Publicado: (2014)

Trivalent Gd-DOTA reagents for modification of proteins
por: Fisher, Martin J., et al.
Publicado: (2015)

Theoretical Study of Actinide(III)-DOTA Complexes
por: Kovács, Attila
Publicado: (2021)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
por: Han, Zheng, et al.
Publicado: (2019)

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Enhanced Therapeutic Effects of (177)Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts
por: Mohajershojai, Tabassom, et al.
Publicado: (2023)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA(5).SA.FAPi and DOTA.SA.FAPi
por: Moon, Euy Sung, et al.
Publicado: (2021)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the (64)Cu-Labelling of Immunoconjugates
por: Maisonial-Besset, Aurélie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_urign4i4v3c02e5n72mla5p169